Abstract
induced up-regulation of the gp120 CD4-inducible (CD4i) epitope bound by mAb 17B, 36 demonstrating that a conformational change in gp120 may be required for Galcer blocking. One proposed alternate receptor for HIV-1, the glycosphingolipid Galactosyl ceramide 62 (Galcer), is expressed on the surface of colonic epithelial cells (13) (14) (15) , and vaginal epithelium 63 (16, 17) , as well as primary mammary epithelial cells (18) . Antibodies against Galcer have been 64 reported to inhibit epithelial cell-HIV-1 virion binding (7, 8, 19) and previous biochemical uptake of HIV-1 by Galcer expressing mammary epithelial cells have been reported to facilitate 70 infection of CD4 T cells (18) . 71 While the other HIV-1 vaccine efficacy trials were unsuccessful in demonstrating 72 efficacy (26) (27) (28) (29) (30) (31) (32) (33) , the RV144 ALVAC/AIDSVAX trial showed a 31.2% efficacy (34). 
HIV-1 Env Proteins:
The consensus, chronic and T/F type Env gp140 proteins were produced 115 recombinantly as described previously (43).
116
Monoclonal antibodies: The mouse monoclonal antibody anti-galactocerebroside (anti-Galcer 117 mAb (44)) was obtained from Millipore. The 2F5, 4E10 and 2G12 mAbs were purchased from 118 Polymun Scientific (Vienna, Austria). The PG9 mAb was a gift from D. Burton (Scripps 119 Research Institute, La Jolla, CA) and VRC01 mAb was a gift from J. Mascola (National 120 Institutes of Health, Vaccine Research Center, Bethesda, MD). The b12 mAb was procured from 121 Quality Biological (Gaithersburg, MD). The gp41 MPER specific mouse monoclonal antibody 122 13H11 (45) was recombinantly produced as described previously (46). The HIV- 1 Env IgG 123 antibodies from RV144 vaccinees were generated as described earlier (36). The CH38 IgA2 and 124 7B2 IgA2 antibodies were made recombinantly using protocols published earlier (37). The HIV- PBS buffer (control) and the remaining two were dipped into anti-Galcer mAb (150 µg/ml) for control another anti-Galcer pre-coated Galcer liposome sensor was dipped in to PBS.
161
Subsequently all these sensors were dipped into PBS to follow dissociation for 30 minutes.
162
Blank APS sensors were used in parallel to subtract out binding due to non-specific interactions.
163
For Galcer blocking assay, the Galcer liposome binding of 1086.C gp140 at 50 µg/ml 164 was monitored for 30 minutes and dissociation was monitored for 1 hr. In parallel Galcer Surface plasmon resonance (SPR) assay: All SPR assays were performed using a Biacore 180 3000 instrument at 25°C and data analyses were done using BIAEvaluation 4.1 software. The 181 17B mAb upregulation assay was performed using a CM5 chip immobilized with 17B mAb (6000-7000 RU) by standard amine coupling procedure in three flow cells. The fourth flow cell 183 was immobilized with 6000 RU of Synagis (47), and used as a negative control surface to 184 subtract out responses due non-specific interactions. The T/F HIV Env 1086.C gp140 (40 185 µg/ml) was flowed over the antibody surfaces at a 20 µl/minute flow rate for 2 minutes.
186
Dissociation was followed for 500 s after the injection of Env protein was over. In order to 187 measure 17B upregulation 1086.C gp140 (40 µg/ml) was mixed with the antibodies (100 µg/ml) 188 listed in Table 1 and injected over antibody surfaces. The binding data were processed to obtain Galcer. There was no significant clade differences in Galcer binding of Env gp140 proteins 274 studied here (Table S1 ). The majority of the chronic virus Env gp140 we have tested (4/7) 275 showed strong binding to Galcer liposomes while others were relatively weaker. The Galcer Figure 4D ). Remarkably, the three gp120 C1 antibodies (CH77, CH78 and 331 CH94) that failed to block Galcer binding (outliers in Figure 4C ) did not upregulate 17B binding 332 of 1086C gp140 (circled in Figure 4D ). The CH29 and CH92 mAbs did not bind 1086C gp140 CD4i epitope is exposed while the Galcer binding site is simultaneously masked/disrupted 418 ( Figure 8B ). A second class of C1-specific antibodies include the Galcer non-blocking mAbs-419 those that neither induce CD4i nor mask Galcer binding site ( Figure 8C ). A32 mAb, the third 420 class of antibody, is an exception in that it up-regulates CD4i epitope but does not block Galcer. (sCD4), gp120 CD4 binding site specific mAbs VRC01 and b12, CD4 induced (CD4i) epitope binding mAb 17B with and without sCD4, gp120 V3 loop specific mAbs 19B and F39F, glycan specific gp120 mAb 2G12, glycan dependent gp120 V1V2 mAbs PG9 and CH01, gp120 first constant (C1) region specific mAb A32 and gp41 immunodominant loop specific mAb 7B2 and gp41 membrane proximal external region specific mAbs 2F5, 4E10 and 13H11 is shown. B: The ability of blocking of Galcer binding of 1086.C gp140 by RV135/144 vaccinee antibodies that are specific to gp120 V3 region (CH23), gp120 C1 region (CH29-CH94) and specific to gp120 V1V2 region (CH58 and CH59) is compared. The %Blocking data and the error bars shown are from two separate measurements. C: The correlation between blocking of Galcer binding and 1086.C gp140 binding is shown for RV135/144 C1 IgG antibodies. The solid line is the p g g gp g g linear fit of the data excluding the outliers circled. Statistical analysis that was performed excluding the outliers (N=11) yielded a Spearman correlation coefficient of 0.8349 and a P value of 0.0014. D: The % Blocking of Galcer binding 1086.C gp140 is correlated with % upregulation of 17B binding of 1086.C gp140 by the RV135/144 C1 IgG antibodies. The solid line is a linear fit of all data. Statistical test was performed including all data (N=14) which resulted in a Spearman correlation coefficient of 0.6496 and a P value of 0.0119. Exclusion of the circled antibodies in the statistical analysis (N=11) resulted in a Spearman correlation coefficient of 0.5597 and a P value of 0.0734. 88.7
The 17B binding experiment was performed and %upregulation was calculated as mentioned in methods. An average of three measurements of 17B binding and the estimated standard deviations are presented.
